4 articles in this category
Strong gross margin and rising analyst confidence signal upside, supported by BofA’s price target hike to $10.40 despite sector headwinds.
Strong non-dilutive Eisai deal and rising analyst targets signal near-term upside for NUVB.
Negative free cash flow and high debt are offset by a 79% hash rate boost and analyst target hikes to $52.54, signaling near-term upside.
Narrowed loss beats estimates and FDA Regenerative Medicine designation for BEAM-101 signal near-term upside, supported by strong analyst momentum.